Attention-Deficit/Hyperactivity Disorder Clinical Trial
Official title:
Real-world Evidence of Duration of Adhansia XR for Treatment of ADHD (RE-DAX): An Open-label Pragmatic Study to Assess the Real-world Effectiveness of Adhansia XR in Treatment of Adult and Adolescent Patients With ADHD in the United States
The purpose of this study is to investigate the treatment effectiveness of Adhansia XR at month-2 after initiation, and the effectiveness of Adhansia XR overall and when compared with the active comparator group (Concerta) over time.
This phase IV study is a prospective, open-label, randomized, pragmatic study to investigate the treatment effectiveness of Adhansia XR at Month-2 after initiation, and the effectiveness of Adhansia XR overall and when compared with the active comparator group (OROS MPH or Concerta) over time. Additional outcome assessments for both treatment arms include Health-Related Quality of Life (HRQoL) during the 6-month follow-up period. The burden of illness (BOI) will be investigated by collecting additional measures such as healthcare resource utilization (HCRU), broader treatment patterns, and comorbidities. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02251743 -
Double-Blind 2-Site Randomized Clinical Trial of Neurofeedback for ADHD
|
N/A | |
Completed |
NCT02226445 -
Treatment Drop-out and Missed Appointments Among Adults With ADHD
|
N/A | |
Completed |
NCT01342445 -
Effects of LDX on Functioning of College Students With ADHD
|
Phase 4 | |
Completed |
NCT00528697 -
A Safety and Efficacy Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
|
Phase 2 | |
Not yet recruiting |
NCT00391495 -
Inflammation in Children With Attention-Deficit/Hyperactivity Disorder
|
N/A | |
Completed |
NCT00494819 -
Validity of ADHD Subtypes Using Neuropsychological Measure
|
N/A | |
Completed |
NCT02217371 -
Role of Circadian and Homeostatic Systems in the Regulation of Wakefulness in Adult Patients With Attention Deficit Disorder With or Without Hyperactivity
|
N/A | |
Completed |
NCT01081132 -
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
|
Phase 3 | |
Completed |
NCT06064942 -
Multiple Family Narrative Therapy for Chinese Families of Children With Attention Deficit Hyperactivity Disorder
|
N/A | |
Completed |
NCT00391729 -
A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
|
Phase 2 | |
Completed |
NCT00191048 -
Treatment With Atomoxetine Hydrochloride in Children and Adolescents With ADHD
|
Phase 4 | |
Terminated |
NCT00554385 -
A Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
|
Phase 2 | |
Completed |
NCT00997984 -
Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorder (ADHD) (The ADHD Tempo Study)
|
Phase 3 | |
Not yet recruiting |
NCT05568446 -
Social VR Based Intervention on Enhancing Social Interaction Skills in Children With AD/HD
|
N/A | |
Completed |
NCT02096952 -
Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
|
Phase 4 | |
Recruiting |
NCT02623114 -
Attention-deficit/Hyperactivity Disorder Translational Center for Identifying Biomarkers
|
Phase 4 | |
Completed |
NCT01351246 -
Guided Self-Help for Parents of Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
|
N/A | |
Completed |
NCT00686933 -
Long Term Safety and Tolerability Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
|
Phase 2 | |
Completed |
NCT00491647 -
Time Perception Deficits and Attention-Deficit/Hyperactivity Disorder
|
N/A | |
Completed |
NCT01081145 -
Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)
|
Phase 3 |